Working… Menu

Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02262806
Recruitment Status : Recruiting
First Posted : October 13, 2014
Last Update Posted : April 27, 2020
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) )

Brief Summary:


- Partial lipodystrophy can cause high blood fat levels and resistance to insulin. This can lead to health problems including diabetes. Researchers have found that the drug metreleptin improves health in people with this disease.


- To test the safety and effectiveness of metreleptin.


  • People age 6 months and older with partial lipodystrophy who
  • have received metreleptin through NIH studies and shown improvement AND
  • cannot get metreleptin other ways.


  • Participants will come to NIH approximately every 6 months during year one, then every 1 2 years. Financial assistance may be available for travel within the U.S.
  • At visits, participants will get a supply of metreleptin to take home for daily injections, or it can be shipped to them inside the U.S. They will have:
  • plastic catheter placed in an arm vein.
  • blood tests, urine collection, and physical exam.
  • oral glucose tolerance test, drinking a sweet liquid.
  • ultrasound of the heart, liver, uterus, and ovaries. A gel and a probe are placed on the skin and pictures are taken of the organs.
  • echocardiogram, which takes pictures of the heart with sound waves.
  • Resting Metabolic Rate taken. A plastic hood is worn over the head while the oxygen they breathe is measured.
  • Participants will have up to 3 DEXA scan x-rays per year.
  • Participants may have:
  • annual bone x-rays.
  • liver biopsies every few years. A needle will be inserted into the liver to obtain a small piece. Participants will sign a separate consent for this.
  • Participants must be seen regularly by their local doctors and have blood tests at least every 3-6 months at home.

Condition or disease Intervention/treatment Phase
Diabetes Lipodystrophy Hyperlipidemia Drug: Metreleptin Phase 3

Detailed Description:

Leptin is an adipocyte-derived hormone that can be thought of as a signal from adipose tissue to the rest of the body conveying information about long-term nutritional status. Patients with lipodystrophy have leptin deficiency secondary to lack of adipose tissue. The combination of leptin deficiency and ectopic lipid deposition in patients with lipodystrophy leads to metabolic complications including severe insulin resistance and diabetes, hypertriglyceridemia, non-alcoholic steatohepatitis, and polycystic ovarian syndrome. Between 2000 and 2014, the NIDDK IRP conducted an open-label clinical trial of the recombinant human leptin analog, metreleptin, in patients with generalized and partial forms of lipodystrophy. This study showed that metreleptin ameliorates metabolic and endocrine abnormalities in lipodystrophy, including reducing food intake, improving insulin resistance and diabetes, reducing ectopic lipid, and normalizing reproduction. Based on these data, metreleptin was approved by the FDA in February, 2014, for patients with generalized, but not partial, lipodystrophy. Our data have shown, however, that a subgroup of patients with partial lipodystrophy do gain medical benefit from metreleptin.

The purpose of this study is twofold:

  • To provide access to metreleptin to patients with partial lipodystrophy who have previously received and derived benefit from metreleptin through NIH studies (protocols 02-DK-0022 and 13-DK-0057).
  • To continue to collect data on the long-term efficacy of metreleptin in ameliorating the metabolic complications of partial lipodystrophy.

Metreleptin will be given at doses of less than or equal to 0.24 mg/kg/day, adjusted based on body weight and metabolic control. Patients will be seen approximately once per year at NIH for evaluation, and potentially less frequently for those who are medically stable and have difficulty traveling to NIH. Laboratory evaluation will be obtained more frequently by the patient s home providers as clinically indicated. The primary outcomes of the study are improvements in serum triglycerides and hemoglobin A1c levels. Secondary outcomes include measures of steatohepatitis and ectopic lipid, body composition, bone mineral density and bone mineral metabolism, and pituitary and reproductive function.

Metreleptin is supplied by Aegerion Pharmaceuticals, Incorporated. Neither the NIH nor Aegerion Pharmaceuticals can guarantee that leptin will be available indefinitely and/or after the study ends.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 35 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Compassionate Use of Metreleptin in Previously-Treated Patients With Partial Lipodystrophy
Actual Study Start Date : October 14, 2014
Estimated Primary Completion Date : July 31, 2025
Estimated Study Completion Date : July 31, 2025

Resource links provided by the National Library of Medicine

Drug Information available for: Metreleptin

Arm Intervention/treatment
Leptin therapy
leptin administered via SC injections BID
Drug: Metreleptin
A leptin analog indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.

Primary Outcome Measures :
  1. Serum hemoglobin A1C [ Time Frame: every 6-12 months ]
    improvement in lab value

  2. Serum triglycerides [ Time Frame: every 6-12 months ]
    improvement in lab value

Secondary Outcome Measures :
  1. Bone mineral density & metabolism [ Time Frame: every 12 months ]
    stable or improvement

  2. Ectopic lipid & body composition [ Time Frame: every 12 months ]
    stable or improvement

  3. Steatohepatosis [ Time Frame: every 12 months ]
    stable or improvement

  4. Pituitary & Reproductive Function [ Time Frame: every 12 months ]
    stable or improvement

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
  • Age greater than or equal to 6 months
  • Partial lipodystrophy (either genetic or acquired)
  • Previously or currently treated with metreleptin under NIH study 02-DK-0022 and/or NIH study 13-DK-0057.
  • Documented metabolic benefit from prior or current metreleptin treatment, defined as one or more of the following:

    • TG reduction greater than or equal to 30% OR
    • HbA1c reduction greater than or equal to 1% OR
    • Decrease in insulin requirements greater than or equal to 40% OR
    • Decrease in episodes of pancreatitis OR
    • Improvement in steatohepatitis OR
    • Withdrawal of metreleptin led to marked worsening of metabolic parameters


  • Availability of metreleptin to the patient either as an approved drug, or through local compassionate use or expanded access programs.
  • Known HIV infection or HIV-associated lipodystrophy.
  • Psychiatric disorder impeding competence or compliance.
  • Any medical condition or medication that will increase risk to the subject.
  • Current alcohol or substance abuse.
  • Subjects who have a known hypersensitivity to E. coli derived proteins.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02262806

Layout table for location contacts
Contact: Megan S Startzell, R.N. (301) 402-6371
Contact: Rebecca J Brown, M.D. (301) 594-0609

Layout table for location information
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)    800-411-1222 ext TTY8664111010   
Sponsors and Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Layout table for investigator information
Principal Investigator: Rebecca J Brown, M.D. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Identifier: NCT02262806    
Other Study ID Numbers: 150002
First Posted: October 13, 2014    Key Record Dates
Last Update Posted: April 27, 2020
Last Verified: April 22, 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ):
Additional relevant MeSH terms:
Layout table for MeSH terms
Lipid Metabolism Disorders
Metabolic Diseases
Skin Diseases, Metabolic
Skin Diseases